Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
Panelists discuss recent data updates on transplant-ineligible and deferred newly diagnosed multiple myeloma (NDMM), including findings from the CEPHEUS and IMROZ studies, and explore the clinical significance of minimal residual disease negativity as a prognostic and actionable factor in treatment decision-making for NDMM.
EP: 1.Highlights from ASH 2024: Optimizing Frontline Therapy in Transplant-Eligible MM
EP: 2.Tailoring Induction Therapy in Newly Diagnosed Transplant-Eligible MM: Key Considerations
EP: 3.AURIGA Trial Highlights: Daratumumab + Lenalidomide Maintenance in Newly Diagnosed MM
EP: 4.Transplant-Ineligible NDMM: Updates from CEPHEUS and IMROZ at ASH 2024
EP: 5.Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials
EP: 6.Strategic Use of Bispecific Antibodies in R/R MM
EP: 7.Sequencing Bispecifics and BCMA-Targeted Therapies in R/R MM
EP: 8.Integrating Bispecific Antibodies Into Clinical Practice
EP: 9.Looking Ahead: Major Clinical Advancements in Myeloma From ASH 2024 and What’s to Come in 2025
EP: 10.Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma
Video content above is prompted by the following:
- Please comment on recent data updates for transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM):
- CEPHEUS study, SubQ Dara-VRd vs VRd in transplant-ineligible NDMM
- IMROZ study, Isa-VRd vs VRd in TIE/deferred NDMM
- What is the clinical significance of minimal residual disease (MRD) negativity as a clinical outcome? How do you interpret and integrate MRD negativity into your clinical decision-making? Beyond its prognostic value, what actionable insights does MRD provide in guiding treatment strategies and patient management?
- Please highlight key insights from MRD analyses in NDMM presented at ASH 2024.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
